We investigated the protective effect of suramin, an enzyme inhibitor and an uncoupler of G protein from receptors, on the myotoxic activity in mice of different crotalid snake venoms (A.c. laticinctus, C.v. viridis, C.d. terrificus, B. jararacussu, B. moojeni, B. alternatus, B. jararaca, L. muta). Myotoxicity was evaluated in vivo by injecting im the venoms (0.5 or 1.0 mg/kg) dissolved in physiological saline solution (0.1 ml) and measuring plasma creatine kinase (CK) activity. Two experimental approaches were used in mice (N = 5 for each group). In protocol A, 1 mg of each venom was incubated with 1.0 mg suramin (15 min, 37ºC, in vitro), and then injected im into the mice at a dose of 1.0 mg/kg (in vivo). In protocol B, venoms, 1.0 mg/kg, were injected im 15 min prior to suramin (1.0 mg/kg, iv). Before and 2 h after the im injection blood was collected by orbital puncture. Plasma was separated and stored at 4ºC for determination of CK activity using a diagnostic kit from Sigma. Preincubation of some venoms (C.v. viridis, A.c. laticinctus, C.d. terrificus and B. jararacussu) with suramin reduced (37-76%) the increase in plasma CK, except for B. alternatus, B. jararaca or L. muta venoms. Injection of suramin after the venom partially protected (34-51%) against the myotoxicity of B. jararacussu, A.c. laticinctus and C.d. terrificus venom, and did not protect against C.v. viridis, L. muta, B. moojeni, B. alternatus or B. jararaca venoms. These results show that suramin has an antimyotoxic effect against some, but not all the North and South American crotalid snake venoms studied here.
Myonecrosis can be a significant consequence of poisoning by snake venom components named myotoxins, and many antivenins are ineffective in antagonizing the activity of these myotoxins (1) (2) (3) (4) . We have previously shown that heparin and other polyanions inhibit the increase of creatine kinase (CK) release induced by crotalid venoms in mice (5) (6) (7) (8) . We ascribed this antagonism to the formation of acid-base complexes between the basic myotoxins of the venoms and the polyanion compounds. There are reports suggesting that some heparinoids exhibit various biological functions (9, 10) and among them, suramin, one of the oldest heparinoids, represents an important target molecule (11, 12) . Suramin is a polysulfonated naphthylamine-amine-benzamide derivative ( Figure 1 ) that has been widely used for more than fifty years in the treatment of onchocerciasis and trypanosomiasis (12) (13) (14) . There are several reports showing that suramin has anti-enzymatic activity by binding basic proteins and it also inhibits the coupling of various metabotropic autonomic receptors to the G proteins. Among the targets, are the G protein subunits in which suramin inhibits guanosine diphosphate release (13, 14) . Suramin blocks cell surface binding of various growth factors and increases tissue glycosaminoglycans (12) (13) (14) . There are also studies showing that suramin can inhibit the neurotoxic effect of ß-bungarotoxin and partially inhibit some pharmacological effects of Cerastes vipera venom (15, 16) .
In the present study we investigated the antagonism or protection of the myotoxic effect of some North and South American snake venoms by this polysulfated substance. Experiments were performed with Bothrops jararacussu and B. jararaca venoms obtained from Instituto Vital-Brazil (Niterói, RJ, Brazil), B. alternatus, B. moojeni, and Crotalus durissus terrificus venoms from the Instituto Butantan (São Paulo, SP, Brazil), whereas C. viridis viridis (prairie rattlesnake) and Agkistrodon contortrix laticinctus (broad-banded copperhead) venoms were obtained from the Venom Research Laboratory (Oklahoma State University, Stillwater, OK, USA). Lachesis muta venom and suramin were purchased from Sigma (St. Louis, MO, USA). All other compounds were of analytical grade.
Venoms, whose quantity is reported as mg protein and whose protein concentration was estimated as described by Fuly et al. (17) , were dissolved in physiological saline solution (PSS; 0.1 ml) and injected im into the thigh of Swiss mice (20-25 g). Venom was injected at a dose of 1.0 mg/kg, except for C.d. terrificus venom or B. jararaca, which was injected at the dose of 0.5 mg/kg. Previous studies showed that im injection of 0.1 ml PSS has no effect on plasma CK levels (5) (6) (7) (8) .
Two experimental protocols were used. In protocol A, 1.0 mg/ml of suramin and 0.5-1.0 mg venom/ml were incubated together for 15 min at 37ºC (in vitro), and then injected im, 1 mg venom/kg, into each animal (in vivo). In protocol B, each venom was administered im to the animals 15 min before the intravenous injection of suramin (1.0 mg/kg). In both protocols the final volume of venom injected, alone or plus suramin, was 0.1 ml. The venom doses were selected based on previous studies (5) (6) (7) (8) . The animals were lightly anesthetized with diethyl ether immediately before and 2 h after venom injection for blood collection according to the guidelines for care and use of laboratory animals (18) . Plasma was separated by centrifugation and stored at 4ºC for subsequent determination of CK activity. The procedure for the measurement of CK activity has been described previously (1, (5) (6) (7) (8) . Enzyme activity is reported as international units per liter (U/l), where 1 U is the amount that catalyzes the transformation of 1 µmol of substrate at 25ºC. Figure 2 shows that im injections of all crotalid crude venoms induced a significant increase in plasma CK activity compared to PSS. B. jararacussu venom injection increased CK levels from 71.16 ± 7.44 (mean ± SEM, N = 5) to 5384. 8 Figure 1 . Structure of suramin, a polysulfonated naphthylurea (molecular weight 1429).
protection against the myotoxicity of B. alternatus, L. muta (Figure 2) (Figure 2) or B. jararaca venom (data not shown). It is interesting to note that, in protocol B, suramin was less effective in antagonizing the myotoxic effect of some venoms which present very active hemorrhagic toxins in their composition (18) (19) (20) . In summary, these data show that suramin protects against the myotoxic effect of some (B. jararacussu, C.d. terrificus and A.c. laticinctus), but not all (C.v. viridis, B. moojeni and L. muta) venoms in both protocols. Some closely related venoms (B. alternatus and B. jararaca) sometimes gave opposite results. The present results extend previous observations showing that polysulfated substances neutralize the toxicity of some crotalid venoms, which have been reported to contain basic myotoxic phospholipases A 2 (PLA 2 ; 2,4,8,18). These myotoxic PLA 2 present in some crotalid venoms are either Asp-49 catalytically active variants or Lys-49, enzymatically inactive homologues (4, 18) . However, suramin offered no protection against the myotoxicity of Bothrops venoms (B. alternatus or B. jararaca) whose study did not reveal basic myotoxic PLA 2 (18) . Like heparin, suramin did not protect against the myotoxicity of L. muta venom, in agreement with our previous data (17) . These results indicate that suramin has a significant antivenom effect against some crotalid snake venoms. It partially reproduces the antimyotoxic effect previously described for other polysulfated substances (5, 6, 8) and deserves further study to evaluate its antimyotoxic activity and therapeutic potential as an antivenin.
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